Skip to main content

Volume 21 Supplement 1

Results from the Phase I study programme for navafenterol (AZD8871), a novel inhaled dual pharmacology bronchodilator (MABA)

Research

The publication costs for this supplement were funded by AstraZeneca. The articles have undergone the journal’s standard peer-review process. The supplement editors declare no competing interests.

Edited by Arnaud Bourdin and Kelan Tantisira

  1. Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/β2-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, ...

    Authors: Eulalia Jimenez, Carol Astbury, Muna Albayaty, Ulrika Wählby-Hamrén, Beatriz Seoane, Cristina Villarroel, Helena Pujol, Maria Jesus Bermejo, Ajay Aggarwal and Ioannis Psallidas

    Citation: Respiratory Research 2020 21(Suppl 1):211

    Content type: Research

    Published on:

  2. Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β2−agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and to...

    Authors: Dave Singh, Victor Balaguer, Carol Astbury, Ulrika Wählby-Hamrén, Eulalia Jimenez, Beatriz Seoane, Cristina Villarroel, Alejhandra Lei, Ajay Aggarwal and Ioannis Psallidas

    Citation: Respiratory Research 2020 21(Suppl 1):102

    Content type: Research

    Published on:

  3. Navafenterol (AZD8871) is a novel, long-acting, dual-pharmacology (muscarinic receptor antagonist and β2−adrenoceptor agonist) molecule in development for chronic obstructive pulmonary disease and asthma.

    Authors: Victor Balaguer, Muna Albayaty, Eulalia Jimenez, Ulrika Wählby-Hamrén, Carol Astbury, Beatriz Seoane, Marie-Pierre Malice, Alejhandra Lei, Ajay Aggarwal and Ioannis Psallidas

    Citation: Respiratory Research 2020 21(Suppl 1):212

    Content type: Research

    Published on:

Annual Journal Metrics